Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05386459 Completed - Clinical trials for COVID-19 Respiratory Infection

Study of the Use of the Drug Ingaron in Patients With COVID-19

Start date: April 21, 2020
Phase:
Study type: Observational

Interferon gamma is a powerful endogenous regulatory cytokine that activates the antiviral immune response, while it also has its own antiviral activity. The objective of this study was to evaluate the effectiveness of the proposed treatment regimen with Ingaron (INN: recombinant interferon gamma human, lyophilisate for preparing a solution for intramuscular and subcutaneous administration of 500,000 IU) in patients with viral pneumonia.

NCT ID: NCT05386446 Completed - Clinical trials for COVID-19 Respiratory Infection

Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19

Start date: April 23, 2020
Phase:
Study type: Observational

The main purpose of this study is to evaluate the effectiveness of the prophylactic use of Ingaron (INN: recombinant interferon gamma human, lyophilisate for solution for intranasal administration 100,000 IU) in the regimen of 3 drops in each nasal passage intranasally every other day for 10 days with a break of 7 days (2 10-day cycles) in volunteers.

NCT ID: NCT05385029 Completed - Hypothyroidism Clinical Trials

Fetal and Neonatal Thyroid in Pregnancies With Severe Acute Respiratory Syndrome Coronavirus 2 ( SARS- COV2 ) COVID-19

COVID-19
Start date: May 1, 2020
Phase:
Study type: Observational [Patient Registry]

The thyroid gland has been shown to be a common target for COVID 19 virus. Babies born to mothers positive for COVID 19 infections were noticed to have elevated thyroid stimulating hormone ( TSH ) levels on screening. Thyroid function tests were monitored in these babies to determine presence of temporary or permanent thyroid disorders following COVID 19 infections during pregnancy.

NCT ID: NCT05384886 Completed - COVID-19 Clinical Trials

Impact of New Variants and Vaccines on the Course of COVID-19

COVID-19
Start date: January 1, 2022
Phase:
Study type: Observational

Novel coronavirus disease (COVID-19), caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, was first reported in December 2019 in Wuhan, China. The disease has spread to many countries in a few weeks and has become a global public health problem. By 2022, the virus has infected more than 500 million people worldwide and caused more than 6 million deaths. Case fatality rates (CFR) are an important index that helps to understand the epidemiological characteristics of an epidemic. In the data coming in 2020, COVID-19 CFR values were generally reported in the range of 0.001-0.706. However, from 2019 to 2022, there were 2 major changes that could affect the CFR of the disease. The first of these is vaccine applications, and the second is the new variants of SARS-CoV-2, which appeared first. From 2019 to 2022, it is likely that there will be a change in the mortality of COVID-19 in relation to both the vaccines administered and the new variants emerging. However, the data on this subject are not clear yet and more studies are needed. The aim of this study is to determine whether there is a change in the mortality of COVID-19 from 2019, when it first appeared, to 2022.

NCT ID: NCT05379621 Completed - COVID-19 Clinical Trials

Socio-economic, Meteorological and Environmental Factors Associated With the Incidence of COVID-19

Start date: January 3, 2021
Phase:
Study type: Observational

Socio-demographic factors in relation to the diagnosis of COVID cases are increasingly mentioned in the role of transmission, but unfortunately with a small number of conclusive publications on French data. Our objective is to analyse the distribution of cases according to these factors and their possible role during the first 6 weeks of 2021 when the Alpes Maritimes was the department with the highest incidence rate. The collaboration between ARS06 and the Public Health Department in the field of COVID-19 has made it possible to have a departmental bulletin for monitoring the evolution of the epidemic (incidence, screening, hospitalisation). Knowledge of the socio-demographic, meteorological and environmental factors associated with the transmission of SARS-CoV2 would make it possible to reflect on how to act on these factors and to implement a public health policy.

NCT ID: NCT05379465 Completed - Clinical trials for Career Choice of Medicine

The Impact of the COVID-19 Pandemic on the Career Choice of Medicine

Start date: October 16, 2020
Phase:
Study type: Observational

The aim of this study is to determine what impact the COVID-19 pandemic may have had on the choices of high school students to pursue medicine as a career.

NCT ID: NCT05375058 Completed - COVID-19 Clinical Trials

Complicated Appendicitis During the COVID-19 Pandemic in Jordan

Start date: March 2, 2019
Phase:
Study type: Observational

Comparing the incidence of complicated appendicitis between two groups, the pandemic and pre-pandemic groups.

NCT ID: NCT05374668 Completed - Post-COVID-19 Clinical Trials

The Effects of Video-based Yoga Interventions for Patients With Post-corona Virus Disease

Yoga
Start date: March 22, 2021
Phase: N/A
Study type: Interventional

Aimed to understand if yoga exercises are superior to posture exercises as an alternative exercise therapy for relieving musculoskeletal pain, improving functional status, and improving quality of life during the post- corona virus disease (COVID-19) period?

NCT ID: NCT05373420 Completed - COVID-19 Clinical Trials

COVID-19 Vaccination Uptake in Belgium : Sociodemographic and Socioeconomic Disparities

Start date: December 28, 2020
Phase:
Study type: Observational

In January 2021, the vaccination campaign against coronavirus disease 2019 (COVID-19) started in Belgium. The vaccination campaign was conducted in several phases, with the first phase targeting priority groups starting in January 2021. The second phase began in June 2021 with the invitation of everyone aged 18 years and older before extending access to 12 years and older from summer 2021. Children aged 5-11 were also invited for vaccination from December 2021 onwards. The presence of a social gradient in COVID-19 infections and subsequent outcomes has been clearly demonstrated. Individuals from lower socioeconomic groups, for example with lower income, lower education level or unemployed are more likely to be infected by the SARS-CoV-2 and to develop severe complications after the infection such as hospitalization, ICU admission or death. Certain sociodemographic characteristics such as male gender, older age, living in crowded households, or belonging to ethnic/racial minorities are also associated with a higher risk of COVID-19 infection and severe outcomes. In addition to disparities in infection, hospitalization and mortality, some studies have also documented a lower COVID-19 vaccination coverage among people from disadvantaged socioeconomic groups during COVID-19 pandemic. Despite widespread vaccine promotion efforts and the fact that Belgium has the 7th highest full vaccine coverage in the European Union (89% of people over 18 years old had completed their primary course of vaccination on 08 April 2022), concerns regarding vaccine equity remain. Vaccine uptake depends on a range of factors, including the socio-cultural environment, pre-existing health needs and individual choice. Identifying differences in vaccination between population groups is crucial to assess the effectiveness of the vaccination strategy in Belgium and its relationship to the further spread of COVID-19. Our objective is to identify whether vaccination coverage has been equitable across Belgium and, if not, which groups of individuals are less likely to be covered by the COVID-19 vaccine, with respect to their sociodemographic (SD) and socioeconomic (SE) characteristics. This study therefore aims to highlight SD and SE disparities in the uptake of the first dose of COVID-19 vaccine in Belgium among people of 18 years and over.

NCT ID: NCT05371561 Completed - COVID-19 Clinical Trials

Effect of PPE on Children's Fear in Dental Office

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

the aim of the current study is to compare the effect of conventional facial PPE as 1)goggles + surgical masks, and 2)face shields + surgical masks versus 3)half-face and 4)full-face reusable respirators; on preoperative child's fear in the dental office.